Argenx Stock Surges As Amgen Struggles To Take On 'The King' In Autoimmune Diseases

Argenx Stock Surges As Amgen Struggles To Take On 'The King' In Autoimmune Diseases · Investor's Business Daily
ALLISON GATLIN
3 min read

In This Article:

Argenx stock surged Wednesday after Amgen presented "underwhelming" results for a potential competitor to Vyvgart in an autoimmune disease.

Recommended Stories